Quantification of increased biologically active CXCL12α plasma concentrations after ACKR3 antagonist treatment in humans

• Главные авторы: Peter Blattmann (Автор), Hervé Farine (Автор), Brian Dan (Автор), Nicole Stiffler (Автор), Thomas Lefebvre (Автор), Christine Huynh (Автор), Patricia N. Sidharta (Автор), Jasper Dingemanse (Автор), Richard W. D. Welford (Автор), Marcel Keller (Автор), Daniel S. Strasser (Автор)
• Формат: ‌
• Опубликовано: Wiley, 2024-02-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract CXCL12 acts as a chemoattractant by binding to the receptor CXCR4. The (atypical) chemokine receptor ACKR3 (CXCR7) scavenges CXCL12. Antagonism of ACKR3 thus leads to an increase in CXCL12 concentrations that has been used as a pharmacodynamic biomarker in healthy adults. Increased CXCL12 c...